Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome

G. Grugni, G. Guzzaloni, F. Morabito

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 μg/kg, iv) or GHRP (1 μg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4±2.0; AUC: 588±113; nAUC: 483±108) and GHRH+PD (GHp: 7.3±1.8; AUC: 486±122; nAUC: 371±250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7±3.2, p

Original languageEnglish
Pages (from-to)340-348
Number of pages9
JournalJournal of Endocrinological Investigation
Issue number5
Publication statusPublished - 2001


  • GH
  • GHRP-6
  • Obesity
  • Prader-Willi syndrome
  • Short stature

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome'. Together they form a unique fingerprint.

Cite this